Literature DB >> 20032415

The Akt and ERK activation by platinum-based chemotherapy in ovarian cancer is associated with favorable patient outcome.

Tsuyoshi Ohta1, Masanori Isobe, Toshifumi Takahashi, Maki Saitoh-Sekiguchi, Teiichi Motoyama, Hirohisa Kurachi.   

Abstract

AIM: To investigate the phosphatidylinositol 3-kinase (PI3K)-Akt and extracellular signal regulated protein kinase (ERK) activation by chemotherapy, and the relationship between the activation of them and patient outcomes. The effect of chemotherapy on the cell proliferation and apoptosis markers and their role in the biology of ovarian cancer were also investigated.
MATERIALS AND METHODS: This study was carried out in a series of 10 ovarian (or tubal) cancer patients whose specimens were obtained before and after chemotherapy. PI3K-Akt and ERK activation were evaluated by immunohistochemical staining for phosphorylated Akt and ERK. Their correlation with patient outcome was investigated by survival curves using the Kaplan-Meier method. Cell proliferation was evaluated by Ki-67 expression using immunofluorescent staining. Apoptosis was examined by caspase-3 and cleaved Poly ADP ribose polymerase (PARP) using immunofluorescent staining.
RESULTS: An increase in Akt and ERK phosphorylation after chemotherapy was observed in 5 and 8 patients, respectively out of 10 patients examined. Akt and ERK activation by chemotherapy were associated with a favorable overall survival. In almost all patients, Ki-67 expression was initially high and largely decreased after chemotherapy. An increase in apoptotic marker expression was observed in almost all patients exposed to chemotherapy.
CONCLUSION: Our findings suggest that Akt and ERK activation by chemotherapy may be associated with favorable prognosis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20032415

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  13 in total

1.  ARK5 is associated with the invasive and metastatic potential of human breast cancer cells.

Authors:  Xin-Zhong Chang; Jie Yu; Hai-Yin Liu; Rui-Hua Dong; Xu-Chen Cao
Journal:  J Cancer Res Clin Oncol       Date:  2011-11-22       Impact factor: 4.553

2.  SPARCL1 suppresses the proliferation and migration of human ovarian cancer cells via the MEK/ERK signaling.

Authors:  Yan Ma; Yuan Xu; Li Li
Journal:  Exp Ther Med       Date:  2018-08-07       Impact factor: 2.447

3.  Inhibition of AMPK-related kinase 5 (ARK5) enhances cisplatin cytotoxicity in non-small cell lung cancer cells through regulation of epithelial-mesenchymal transition.

Authors:  Minghui Li; Chengfei Zheng; Hongfei Xu; Wei He; Yongchun Ruan; Jianyong Ma; Junnan Zheng; Chengmeng Ye; Weidong Li
Journal:  Am J Transl Res       Date:  2017-04-15       Impact factor: 4.060

4.  Cisplatin and paclitaxel co-delivery nanosystem for ovarian cancer chemotherapy.

Authors:  Qiaoying Wang; Changqiang Wu; Xiaoting Li; Dixiao Yang; Liangjun Shi
Journal:  Regen Biomater       Date:  2021-06-14

Review 5.  Oncogenes associated with drug resistance in ovarian cancer.

Authors:  Xia Liu; Yutao Gao; Yi Lu; Jian Zhang; Li Li; Fuqiang Yin
Journal:  J Cancer Res Clin Oncol       Date:  2014-07-06       Impact factor: 4.553

6.  Overexpression of ARK5 is associated with poor prognosis in hepatocellular carcinoma.

Authors:  Jing Cui; Yong Yu; Gao-Feng Lu; Chao Liu; Xia Liu; Yu-Xian Xu; Peng-Yuan Zheng
Journal:  Tumour Biol       Date:  2013-03-21

Review 7.  Role of ARK5 in cancer and other diseases (Review).

Authors:  Guoheng Mo; Bohan Zhang; Qunguang Jiang
Journal:  Exp Ther Med       Date:  2021-05-02       Impact factor: 2.447

8.  ARK5 promotes invasion and migration in hepatocellular carcinoma cells by regulating epithelial-mesenchymal transition.

Authors:  Zhiyu Ye; Xudong Chen; Xiaogang Chen
Journal:  Oncol Lett       Date:  2017-11-21       Impact factor: 2.967

9.  Co-delivery of carboplatin and paclitaxel via cross-linked multilamellar liposomes for ovarian cancer treatment.

Authors:  Xiaoyang Zhang; Yarong Liu; Yu Jeong Kim; John Mac; Rachel Zhuang; Pin Wang
Journal:  RSC Adv       Date:  2017-04-03       Impact factor: 3.361

10.  Predictive and prognostic protein biomarkers in epithelial ovarian cancer: recommendation for future studies.

Authors:  Cécile Le Page; David G Huntsman; Diane M Provencher; Anne-Marie Mes-Masson
Journal:  Cancers (Basel)       Date:  2010-05-26       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.